Growth Inhibition of Multidrug-Resistant Cells by Monoclonal Antibodies against P-Glycoprotein

Abstract

When cell lines are made resistant to naturally occurring anticancer agents such as Vinca alkaloids or anthracyclines, they usually show cross-resistance to certain other drugs to which they have not been previously exposed (for reviews, see Chapters 1 and 2). The classes of agents to which this cross-resistance extends are diverse, but the drugs are all complex high-molecular-weight natural products. The basis for this multidrug-resistant (MDR) phenotype appears to be a membrane change that results in decreased uptake of these drugs (Riordan and Ling, 1985; Skovsgaard, 1978; Inaba et al., 1979). All of these agents presumably utilize a similar transport system, despite the wide disparity in their structures.

Brox, A., Price, G., and Sullivan, A. K., 1985, An antigen related to the phenotype of multidrug resistance can be induced in vivo and used as a target for immunotherapy of rat leukemia, Leuk. Res. 9:987–992.PubMedCrossRefGoogle Scholar